Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Development of Blood Vessels01:07

Development of Blood Vessels

1.6K
The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
1.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K
Hematopoiesis01:21

Hematopoiesis

9.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.5K
Veins of Head and Neck01:19

Veins of Head and Neck

6.5K
The blood drainage from the head and neck is primarily managed by three pairs of veins: the external jugular, internal jugular, and vertebral veins. The external jugular veins drain superficial scalp and face structures, passing over the sternocleidomastoid muscles to empty into the subclavian veins.
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
6.5K
Skin Cancer01:30

Skin Cancer

6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Insights Into Poikiloderma With Neutropenia: Genotypic and Phenotypic Analysis of 90 Cases With a New Case Report.

American journal of medical genetics. Part A·2026
Same author

Higher Doses of Oral Propranolol for Resistant Infantile Haemangio-mas.

Acta dermato-venereologica·2026
Same author

Diagnosis and management of infantile hemangiomas: Tremendous advances over the last 15 years.

Presse medicale (Paris, France : 1983)·2025
Same author

Fulminant parvovirus B19 myocarditis in infants -report of three post-pandemic cases.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

Ustekinumab for pyoderma gangrenosum-like skin ulcerations in late-onset leukocyte adhesion deficiency.

The journal of allergy and clinical immunology. Global·2024

関連する実験動画

Updated: Mar 8, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

654

幼児の血管腫

Christine Léauté-Labrèze1, John I Harper2, Peter H Hoeger3

  • 1Department of Dematology, Pellegrin Children's Hospital, Bordeaux, France.

Lancet (London, England)
|January 17, 2017
PubMed
まとめ
この要約は機械生成です。

乳児の良性腫瘍である乳児血栓腫は 治療なしで治る事が多い. 合併症を防ぐために,口服プロプラノロールによる早期介入が推奨されます.

さらに関連する動画

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K

関連する実験動画

Last Updated: Mar 8, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

654
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K

科学分野:

  • 小児腫瘍学
  • 皮膚科
  • 血管の異常

背景:

  • 乳児の血液血管腫 (IHs) は,乳児における最も一般的な良性腫瘍であり,新生児の4. 5%に罹患する.
  • IHは通常,人生の最初の数週間に急速に成長し,その後自発的に発現します.
  • ほとんどのIHは治療を必要としませんが,いくつかのケースではリスクのために介入が必要になります.

研究 の 目的:

  • 幼児の血管腫の管理について説明します.
  • IHsの治療のための危険因子と指示を特定する.
  • 早期プロプロノロール治療の役割を強調する.

主な方法:

  • 幼児の血管腫の管理に関する現在の文献と臨床ガイドラインのレビュー.
  • IHの増殖をモニタリングするための重要な時間点を特定する.
  • 経口プロプロノロールの治療用薬および有効性の評価

主要な成果:

  • IHの80%は3ヶ月までに最終的なサイズに達し,早期のフォローアップの必要性を強調しています.
  • 治療の指示には,生命を脅かすIH,機能的リスク (視覚,栄養),潰瘍,美容的歪みが含まれます.
  • 口服プロプラノロールはファーストラインの治療法であり,迅速な縮小を示し,最低6ヶ月の治療が必要です.

結論:

  • 早期発見とモニタリングは,リスクのある幼児の血管腫を特定するために不可欠です.
  • 口服プロプラノロールは,介入を必要とする内臓炎症に対する安全で効果的な第一線治療法です.
  • プロプラノロールの治療を適時に開始すると,乳児の血管腫に関連する重篤な合併症を防ぐことができます.